The serum transferrin receptor (TfR) level reflects iron status and the rate of erythropoiesis. This study was undertaken to assess the role of serum TfR in the iron status and erythropoiesis in very-low-birth-weight infants under conditions in which erythropoiesis is stimulated by large doses of recombinant human erythropoietin (rHuEPO) and oral iron. The first 34 infants were followed from the 3rd to llth wk of life or until discharged. They received iron at a rate of 3 mglkgld. The subsequent 21 infants were given rHuEPO (300 U/kg three times a week s.c.) and iron at a rate of 6 mglkgld from the 3rd or 4th wk of life for a mean of 3.4 wk. With this treatment, the need for transfusion was reduced from 1.4 2 0.4 to 0.1 2 0.1 transfusions per infant @ = 0.02). The serum TfR concentrations in the rHuEPOtreated infants increased gradually to values several-fold higher than those in the untreated infants. This increase was not related to intrauterine or postnatal growth, protein rHuEPO has been used in the treatment of anemia of prematurity accompanied by a low rate of erythropoiesis and low serum concentrations of erythropoietin (1) (2) (3) (4) (5) (6) (7) (8) . Several studies have provided evidence for the efficacy of rHuEPO in stimulating erythropoiesis and reducing the requirement for transfusions. For enhanced erythropoiesis, extra iron is needed. However, it is not certain whether this need can be met by any oral dose of iron (5).
Serum TfR is a new measure that reflects iron status and the rate of erythropoiesis (9-14). In healthy adults, it is present in concentrations of approximately 5 mg/L (10). It becomes elevated soon after signs of iron deficiency appear, and the rise reflects the paucity of available tissue iron. However, the elevated serum TfR level may also be explained by an increase in the erythroid precursor cell mass, and direct effects of erythropoietin intake, or serum albumin concentration. Neither was an association observed between Hb and TfR concentration. In the treated infants, the serum ferritin concentration was lower at the 4th, 5th, and 7th wk of life than in the untreated infants. The very-low-birth-weight infants who were given large doses of rHuEPO and iron had a marked rise in serum TfR concentration and a small decline in serum ferritin concentration. These events have been related to iron deficiency. This study was undertaken to investigate the relationships between the serum TfR concentration and the iron status and rate of erythropoiesis in VLBW infants (birth weight less than 1500 g) in whom erythropoiesis is stimulated by large doses of rHuEPO and oral iron.
METHODS
We studied 55 consecutive VLBW infants. Infants with heart disease, other than patent ductus arteriosus, or with bronchopulmonary dysplasia needing more than 40% oxygen at 2 wk of age were excluded from the study. The included infants had been weaned from the respirator by 2 wk of age.
The first 34 infants were followed from the 3rd wk until discharged or up to the l l t h wk. The subsequent 21 infants were similarly followed, but they were treated with rHuEPO (300 U/kg three times a week s.c.) (Cilag A.G., Schaffhausen, Switzerland). Our aim was to give the rHuEPO treatment during 4 wk, but because of early discharges, the average period of treatment was 3.4 wk. Treatment was started at the 3rd or 4th wk.
The clinical characteristics of the infants are shown in Table 1 . The infants were classified as AGA or SGA (birth weights below -2 SD for gestational age) according to Finnish intrauterine growth charts (17). The cord was clamped in all cases within 15 s. Postnatal growth was analyzed by measuring the increment in body weight each week.
Protein intake. Protein intake was quantified at the 4th and 7th wk of life. It was calculated on three nonconsecutive days in each week. Mean values are given for both weeks.
Iron supplementation. Oral iron supplementation was started at 2 wk of age. The dose was gradually increased to 3 mg/kg/d by the age of 3 wk, which is a routine practice in Finland (18) . However, iron at a rate of 6 mg/kg/d divided into three doses was given to the rHuEPO-treated infants during the treatment period to meet the increased iron needs. During the treatment period, the untreated infants received an average of 114 mg of iron and the treated infants 257 mg of iron. Vitamin (A, B,,, C, D, E, and folic acid) supplementation was given to all infants.
Transhion policy. Infants were given red blood cell transfusions, 10 mL/kg, on the 1st d of life if they had any respiratory decompensation. The hematocrit values were maintained above 0.30. However, infants with symptoms or signs of anemia received transfusions if the hematocrit value was below 0.40. The estimated blood losses for repetitive laboratory investigations were replaced by red blood cell transfusions until the age of 4 wk. Informed consent to the protocol was obtained from the parents. The study was approved by the ethical committees.
Side eflects. Blood pressure was measured during the rHuEPO treatment before and 2-8 h after each injection. A granulocyte count was obtained weekly.
Infections. Ten of the 34 untreated infants and three of the 21 treated infants received antibiotics during the study period.
Laboratory investigations. We collected blood samples weekly from the 3rd to l l t h wk of age (a mean of 4.9 Statistical analysis. For statistical analyses, the unpaired, two-tailed t test, the Mann-Whitney U test, and simple regression analysis were used as appropriate. A p value of ~0 . 0 5 was considered significant. Means k SEM are used unless otherwise mentioned.
RESULTS
In the rHuEPO-treated infants, the concentration of serum TfR became elevated during the treatment and thereafter returned to the level of the untreated infants within 3 wk (Fig. 1) . The concentration remained stable from the 3rd to the l l t h wk of life in the VLBW infants without rHuEPO treatment.
The In the infants receiving rHuEPO, the reticulocyte count was higher than in the untreated infants from the 3rd until the 5th wk of life (4.5 2 0.5% versus 2.5 + 0.3%, p = 0.0003, at the 3rd wk; 6.8 + 0.6% versus 3.9 2 0.6%, p = 0.002, at the 4th wk; and 6.7 + 0.6% versus 4.5 + 0.6%, p = 0.004, at the 5th wk of life). There were no associations between the serum concentration of TfR and the reticulocyte count in the treated infants. In the untreated infants, the serum concentration of TfR and the reticulocyte count were associated at the 3rd, 4th, and 5th wk of life. In Figure 2 , we plotted the relationship between the mean TfR concentration and the mean reticulocyte count from the 5th to the 8th wk of life. There was no association between reticulocyte counts and transfused red blood cell volumes. Total circulating erythrocyte volume was higher in the treated than in the untreated infants from the 3rd until the 7th wk of life. There was no association between the serum concentration of TfR and total circulating erythrocyte volume in either group. The mean difference in total circulating erythrocyte volumes between the treated and untreated infants during the treatment period was 10.5 mL/wk. Thus, the rHuEPO-treated infants have pro- The serum ferritin concentration was lower in the treated than in the untreated infants at the 4th, 5th, and 7th wk of life (Fig. 1) . The serum concentrations of TfR and ferritin correlated inversely at the 4th ( p = 0.008, r = 0.57) and 5th ( p = 0.003, r = 0.68) wk of life in the treated infants. There were no associations between the serum concentrations of TfR and ferritin in the untreated infants. According to Lundstrom et al. (20) , the serum ferritin concentration in low-birth-weight infants receiving iron at a rate of 2 mg/kg/d is about 150 kg/L at the age of 1 mo and about 75 kg/L at the age of 2 mo.
Need for additional iron in the rHuEPO-treated infants was substantial. The large amount needed is explained by the great difference in transfusion volumes and the small difference in Hb concentration between the treated and untreated infants. Two of the 21 treated infants and 16 of the 34 untreated infants received red blood cell transfusions after the age of 2 wk. Thus, the treatment led to a reduction in the mean number of transfusions per infant from 1.4 2 0.4 to 0.1 2 0.1 ( p = 0.02). Two of the treated infants received a mean of 26 mL of red blood cells. Thus, the 21 treated infants received a mean of 2.5 mL of red blood cells per infant. Because the hematocrit of the red blood cell units was about 0.75, a mean of 1.9 mL of red blood cells was actually given per treated infant. This amount corresponds to 2.1 mg of red cell iron per infant. In the untreated infants, the estimated total volume of blood transfused varied from 12 to 94 mL per infant (mean 38 mL). Thus, the 34 untreated infants received a mean of 18 m L of red blood cells per infant. This corresponds to a mean of 14.9 mg of red cell iron per untreated infant. The difference in transfusion volumes was estimated to represent a mean of 12.8 mg (14.9-2.1 mg) of iron per treated infant. The calculated mean red cell iron of the treated infants at the end of the treatment represented 70 mg of iron. The observed 10% difference in mean Hb concentration between the treated and untreated infants amounts to 7 mg of iron per treated infant. Accordingly, the mean calculated need for iron to compensate for the difference in transfusion volumes (12.8 mg) and in Hb concentrations (7 mg) was 19.8 mg.
The treated infants received iron at a rate of 6 mg/kg/d during the rHuEPO treatment period and thereafter at a rate of 3 mg/kg/d, and the untreated infants received iron at a rate of 3 mg/kg/d during the whole study period. The difference was approximately 143 mg of iron per infant during the treatment period. Thus, the absorption of extra iron should be at least 14% of the orally administered iron (19.8 mg/143 mg = 13.8%).
The serum concentrations of TfR in the AGA and SGA infants were similar. For instance, during the period of rHuEPO treatment, the mean values in the treated infants were 4.9 2 0.4 mg/L in the AGA group and 4.9 f 0.5 mg/L in the SGA group, and the mean values in the untreated infants were 2.2 f 0.2 mg/L in the AGA group and 2.4 f 0.2 mg/L in the SGA group. Furthermore, we observed no association between the serum concentration of TfR and the individual rate of postnatal growth in either the treated or the untreated infants, nor did the treated and untreated infants differ in postnatal growth.
Protein intake at the 4th wk of life was 2.4 f 0.1 and 2.3 2 0.1 g/kg/d, and at the 7th wk of life it was 2.7 f 0.2 and 2.7 f 0.2 g/kg/d in the treated and untreated infants, respectively ( p > 0.05). There were no associations between the serum TfR and protein intake in either group. The serum concentration of albumin at the 4th wk of life was 25.7 + 0.7 and 25.2 2 0.7 g/L, and at the 7th wk of life it was 27.0 2 1.2 and 27.5 2 0.9 g/L in the treated and untreated infants, respectively (p > 0.05). There were no associations between the serum concentrations of TfR and albumin in either group.
The serum concentrations of TfR of the three rHuEPOtreated infants who received antibiotics differed from the others only at the 3rd wk of life (6.4 f 1.4 versus 3.0 2 0.2 mg/L, p = 0.0001). Correspondingly, the serum concentrations of TfR of the 10 infants who had antibiotic treatment and the other untreated infants were similar.
We observed no adverse effects during rHuEPO treatment. No evidence of hypertension was obtained, despite frequent recordings of blood pressure. The mean systolic and diastolic pressures were 64 2 1 and 39 + 1 mm Hg before, and 63 + 1 and 39 2 1 mm Hg 2-8 h after the injection. During the treatment period, the lowest individual absolute granulocyte counts were 414/mm3 and 1296/mm3 in the treated and untreated infants, respectively, and the mean absolute granulocyte counts were 3224 + 309/mm3 and 3091 f 389/mmVp = 0.8) in the treated and untreated infants, respectively.
DISCUSSION
The study provided evidence for the efficacy of rHuEPO in stimulating erythropoiesis and reducing the requirement of transfusions for anemia of prematurity. The rHuEPOtreated infants produced about 1 mL of red cells per kg per d more than the untreated infants. We observed no adverse effects among the 21 rHuEPO-treated infants; blood pressures and granulocyte counts were watched especially closely. Nevertheless, we emphasize that the risk of adverse effects is not yet known; so far there have been only two other reports of 11 and 10 VLBW infants treated with doses similar to or exceeding our dose of rHuEPO (5, 7).
The serum concentration of TfR in these rHuEPOtreated VLBW infants increased gradually to values several-fold higher than those in the untreated infants. Even the relatively high dose of 6 mg/kg/d of iron may still be insufficient and may limit the rate of erythropoiesis when a dose of rHuEPO as large as 900 IU/kg/wk is given. This possibility was supported by the cumulative increase in serum TfR concentration during and at 3 wk after discontinuation of the treatment and by the lower serum ferritin values in the treated infants.
An alternative explanation for the elevated TfR concentration during the treatment is that the rate of erythropoiesis is higher than expected from the pattern of Hb concentration (9, 11). If this is the case, rHuEPO-induced erythropoiesis in VLBW infants could be inefficient or associated with some other type of hemolysis. In fact, the association between the serum concentration of TfR and the reticulocyte count disappeared when the infants were treated with rHuEPO (Fig. 2) . There was no association between the serum concentration of TfR and total circulating erythrocyte volume in either group. The usefulness of TfR as an early indicator of a therapeutic response to rHuEPO treatment needs further study.
We calculated that the absorption of extra iron in the treated infants should be at least 14% of the orally administered iron. The mechanism of enhanced iron absorption may be related to the rHuEPO medication (21).
